Response Monitoring to Neoadjuvant Chemotherapy in Osteosarcoma Using Dynamic Contrast-Enhanced MR Imaging

[1]  Bo Xu,et al.  Correlation between chemotherapy resistance in osteosarcoma patients and PAK5 and Ezrin gene expression , 2017, Oncology letters.

[2]  J. Taki,et al.  Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with 99mTc-MIBI scintigraphy , 2015, Skeletal Radiology.

[3]  D. Basu,et al.  Role of Dynamic MRI and Clinical Assessment in Predicting Histologic Response to Neoadjuvant Chemotherapy in Bone Sarcomas , 2014, American journal of clinical oncology.

[4]  Byung Il Kim,et al.  Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18 F-FDG PET/CT and MRI , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  I. Nöbauer-Huhmann,et al.  Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome , 2014, International Orthopaedics.

[6]  Y. Yamada,et al.  Measurement of Blood Perfusion in Spinal Metastases With Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2013, Spine.

[7]  E. D. de Bont,et al.  Survival Trends and Long-Term Toxicity in Pediatric Patients with Osteosarcoma , 2012, Sarcoma.

[8]  A. W. Simonetti,et al.  Pharmacokinetic analysis based on dynamic contrast‐enhanced MRI for evaluating tumor response to preoperative therapy for oral cancer , 2012, Journal of magnetic resonance imaging : JMRI.

[9]  Qing Ji,et al.  Dynamic contrast‐enhanced magnetic resonance imaging as a prognostic factor in predicting event‐free and overall survival in pediatric patients with osteosarcoma , 2012, Cancer.

[10]  N. Fineberg,et al.  Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2011, Molecular imaging.

[11]  E. Rofstad,et al.  Differentiation between hypoxic and non-hypoxic experimental tumors by dynamic contrast-enhanced magnetic resonance imaging. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  Shishir Rastogi,et al.  Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis , 2011, Pediatric Radiology.

[13]  D. Jeon,et al.  Tumor Volume Increase During Preoperative Chemotherapy as a Novel Predictor of Local Recurrence in Extremity Osteosarcoma , 2011, Annals of Surgical Oncology.

[14]  G. Weinstein,et al.  Prediction of Response to Chemoradiation Therapy in Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging , 2010, American Journal of Neuroradiology.

[15]  Marcelino Bernardo,et al.  The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. , 2010, Diagnostic and interventional radiology.

[16]  Soo-Yong Lee,et al.  Tumor Necrosis Rate Adjusted by Tumor Volume Change Is a Better Predictor of Survival of Localized Osteosarcoma Patients , 2008, Annals of Surgical Oncology.

[17]  W. Yang,et al.  Tumor Volume Change after Chemotheraphy as a Predictive Factor of Disease Free Survival for Osteosarcoma , 2005, Yonsei medical journal.

[18]  W. Yang,et al.  Tumor Volume Change as a Predictor of Chemotherapeutic Response in Osteosarcoma , 2000, Clinical orthopaedics and related research.

[19]  P. Hess,et al.  Measurement of the , 1999 .

[20]  J. Bloem,et al.  Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: review of current imaging modalities , 1998, Skeletal Radiology.

[21]  J. Høie,et al.  Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival , 1995, Cancer.

[22]  P. Pynsent,et al.  The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. , 1994, Clinical radiology.

[23]  D. Vanel,et al.  Osteosarcoma: chemotherapy-induced changes at MR imaging. , 1992, Radiology.

[24]  J. Hermans,et al.  The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. , 1990, AJR. American journal of roentgenology.